News Sentiment

ABT sentiment intelligence

Abbott Laboratories news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 62 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 93.93 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

73/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-1.5% over one week, +6.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 73/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend inactive 6.5% over four weeks
Fair value -15.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 41
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 11
Sector context 1

Sources

Coverage mix

Publishers
Market source 20
TradingView 4
Simply Wall Street 3
24/7 Wall St. 3
GuruFocus 2
Seeking Alpha 2
Quiver Quantitative 2
MarketWatch 2

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 21
Macro sensitivity 3
Guidance 3
Analyst action 3
Regulatory and legal 2
Capital return 2
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Courthouse News Direct company coverage

Employees sue medical giant over excessive healthcare costs

A group of Abbott Laboratories employees has filed a class-action lawsuit alleging they were overcharged for health insurance plans that offered no additional benefits. The suit claims Abbott offered two plans with the same medical coverage but different costs, violating the Empl

Tone
Negative 29/100
Event
Regulatory and legal
Published
15 Jul 2026 17:35
Source
Courthouse News
TradingView Direct company coverage

Reasons to Retain Abbott Stock in Your Portfolio for Now

Abbott Laboratories (ABT) is recommended as a stock to retain due to strong performance in its Nutrition business and growth in emerging markets within its Established Pharmaceuticals Division (EPD). However, potential headwinds include currency fluctuations, a dull macroeconomic

Tone
Positive 63/100
Event
Macro sensitivity
Published
15 Jul 2026 15:37
Source
TradingView
Investing.com Canada Direct company coverage

Benchmark reiterates Buy on Abbott Labs stock ahead of Q2 results

Benchmark has reiterated a Buy rating and $120 price target for Abbott Laboratories (NYSE:ABT) ahead of its second-quarter 2026 results. The firm projects Q2 revenue of $12.504 billion in constant currency, with significant contributions expected from Diabetes Care and the Exact

Tone
Positive 72/100
Event
Earnings
Published
15 Jul 2026 14:36
Source
Investing.com Canada
Simply Wall Street Direct company coverage

Can Abbott (ABT) Turn Freenome Progress Into a Durable Diagnostics-Led Growth Story?

Abbott Laboratories is set to release its Q2 2026 results, following advancements in its diagnostics and medical devices portfolio, particularly in cancer screening and diabetes technology. The company's collaboration with Freenome for blood-based colorectal cancer screening is a

Tone
Positive 67/100
Event
Earnings
Published
15 Jul 2026 06:07
Source
Simply Wall Street
Human Resources Director Direct company coverage

Abbott kept a disciplined manager as pregnant worker's boss, lawsuit alleges

A pregnant clinical specialist is suing Abbott Laboratories and St. Jude Medical, alleging she was forced out weeks before her due date after complaining about her supervisor's pregnancy-based comments. Despite the company disciplining the manager for inappropriate remarks, he re

Tone
Negative 27/100
Event
Regulatory and legal
Published
14 Jul 2026 21:57
Source
Human Resources Director
TradingKey Direct company coverage

Abbott Laboratories Stock (ABT) Closed Down by 3.43% on Jul 14: A Full Analysis

Abbott Laboratories (ABT) stock declined by 3.43% on July 14, driven by investor concerns over ongoing litigation risks related to infant formula and cautious guidance within its medical devices division. Increased competition and pricing pressures in the continuous glucose monit

Tone
Negative 26/100
Event
Guidance
Published
14 Jul 2026 20:37
Source
TradingKey
Seeking Alpha Sector context

MedTech stocks lower as HCA surgery volumes dip (HCA:NYSE)

MedTech stocks experienced a downturn following HCA Healthcare's announcement of lowered full-year earnings outlook and a preliminary Q2 2026 report indicating a drop in surgical procedures. This decline in surgical volumes at the largest for-profit hospital operator in the U.S.

Tone
Negative 30/100
Event
Earnings
Published
14 Jul 2026 18:40
Source
Seeking Alpha
MarketWatch Direct company coverage

Abbott Laboratories stock underperforms Tuesday when compared to competitors

Abbott Laboratories (ABT) stock fell 3.42% on Tuesday, closing at $88.96. This underperformance occurred despite a generally positive day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average seeing gains. This marks the fifth consecutive day of l

Tone
Negative 29/100
Event
Market update
Published
14 Jul 2026 16:35
Source
MarketWatch
TradingView Direct company coverage

Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?

Abbott Laboratories (ABT) is set to release its second-quarter 2026 results on July 16, with analysts expecting a 1.6% EPS growth and 12% revenue increase year-over-year. The company's Diagnostics, Established Pharmaceutical Products, and Medical Devices segments are anticipated

Tone
Positive 64/100
Event
Earnings
Published
14 Jul 2026 13:07
Source
TradingView
富途牛牛 Direct company coverage

Abbott Laboratories To Go Ex-Dividend On July 15th, 2026 With 0.63 USD Dividend Per Share

Abbott Laboratories (NYSE:ABT) is set to go ex-dividend on July 15th, 2026, with a dividend payment of 0.63 USD per share. This information is crucial for investors as it indicates the last day to buy shares to be eligible for the upcoming dividend. The dividend yield and record

Tone
Neutral 50/100
Event
Capital return
Published
14 Jul 2026 09:07
Source
富途牛牛
Investing.com Nigeria Direct company coverage

Rick Larsen makes multiple trades in Abbott Laboratories, Amphenol Corporation and others

Rick Larsen, representing Washington's 2nd congressional district, recently executed several investment portfolio transactions as part of an advisor-driven quarterly rebalancing of his Richard R Larsen IRA account. On July 8, 2026, he sold stocks in Abbott Laboratories and S&P Gl

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 01:53
Source
Investing.com Nigeria
MarketWatch Direct company coverage

Abbott Laboratories stock underperforms Monday when compared to competitors

Abbott Laboratories (ABT) stock fell by 1.94% on Monday to $92.11, marking its fourth consecutive day of losses. This underperformance occurred during a generally negative trading session, with the S&P 500 Index declining by 0.79% and the Dow Jones Industrial Average falling by 0

Tone
Negative 28/100
Event
Market update
Published
13 Jul 2026 16:35
Source
MarketWatch
AlphaStreet Direct company coverage

Abbott Laboratories Q2 2026 Earnings Preview — July 16, Street Expects $1.28 EPS

Wall Street anticipates Abbott Laboratories will report second-quarter 2026 earnings of $1.28 per share on $12.52 billion in revenue, with the consensus reflecting input from 23 analysts. While EPS estimates have stabilized recently, they represent a modest decline from three mon

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 11:41
Source
AlphaStreet
Simply Wall Street Direct company coverage

Tandem Diabetes Care (TNDM) Expands Abbott Compatibility As Undervalued Narrative Faces A Fresh Test

Tandem Diabetes Care (TNDM) has announced that its t:slim X2 insulin pump now integrates with Abbott’s FreeStyle Libre 3 Plus CGM in five European countries. Despite this product expansion, the company's share price has experienced recent weakness, leading to a discussion about w

Tone
Positive 58/100
Event
Market update
Published
13 Jul 2026 09:09
Source
Simply Wall Street
Market source Direct company coverage

Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating

Baird has initiated coverage on Abbott Laboratories (ABT) with an "Outperform" rating and a $121.00 price target, expecting steady top-line and earnings growth, especially from its medical device segment. The firm also anticipates new products and the Exact Sciences integration t

Tone
Positive 67/100
Event
Analyst action
Published
13 Jul 2026 09:07
Source
Market source
Simply Wall Street Direct company coverage

3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build

As inflation pressures build and crude/polypropylene costs rise, investors are looking for defensive large-cap stocks. This article identifies three U.S. healthcare stocks—Abbott Laboratories (ABT), ResMed (RMD), and Stryker (SYK)—that offer essential products and services, makin

Tone
Positive 63/100
Event
Macro sensitivity
Published
13 Jul 2026 08:47
Source
Simply Wall Street
Market source Direct company coverage

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie, though relatively young as a standalone company, has maintained its dividend growth inherited from Abbott, positioning itself as a Dividend King. The acquisition of Apogee Therapeutics for $10.9 billion is a strategic move to bolster its drug pipeline, particularly with d

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Jul 2026 23:06
Source
Market source